TY - JOUR T1 - The use of treatable traits to address COPD complexity and heterogeneity and to inform the care JF - Breathe JO - Breathe DO - 10.1183/20734735.0118-2021 VL - 17 IS - 4 SP - 210118 AU - Katarzyna Duszyk AU - Rebecca F. McLoughlin AU - Peter G. Gibson AU - Vanessa M. McDonald Y1 - 2021/12/01 UR - http://breathe.ersjournals.com/content/17/4/210118.abstract N2 - COPD is complex and heterogeneous with respect to its aetiology, clinical presentation, phenotypes and biological mechanisms. Despite this, COPD is still diagnosed and treated according to simple clinical measures, including airflow limitation, symptoms and exacerbation frequency, leading to failure to recognise the disease's heterogeneity and/or to provide targeted interventions. COPD continues to have a very large burden of disease with suboptimal outcomes for people with the disease, including frequent hospitalisation with exacerbations, rapid lung function decline, multimorbidity and death from respiratory failure. In light of this, there have been increasing calls for a renewed taxonomy with better characterisation of COPD phenotypes and endotypes. This would allow the unravelling of COPD's complexity and heterogeneity, the implementation of targeted interventions and improved patient outcomes. The treatable traits strategy is a proposed vehicle for the implementation of precision medicine in chronic airway diseases. In this review, in addition to summarising the key knowledge on the heterogeneity of COPD, we refer to the existing evidence pertaining to the treatable traits strategy as applied in COPD and discuss implementation in different settings.COPD is a heterogeneous clinical syndrome, which requires deconstruction of its individual components to facilitate targeted treatment and improve individual patient outcomes. https://bit.ly/2YXWgHN ER -